St. Jude Tempo pacemaker shipments under way the week of Jan. 12 following approval of Sylmar facility.
This article was originally published in The Gray Sheet
Executive SummaryST. JUDE TEMPO PACEMAKER SHIPMENTS UNDER WAY THE WEEK OF JAN. 12 following a build-up of inventory at the company's Pacesetter unit manufacturing facility in Sylmar, California. The firm received FDA approval for the Tempo, which incorporates "fifth generation" Minute Ventilation sensor technology, via premarket approval application supplement in August 1997, but decided to defer production until receiving an additional PMA supplement approval to manufacture at the Sylmar site Oct. 16. The systems will cost up to an average of $6,000, depending on model and purchase volume, St. Jude states.
You may also be interested in...
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.